Online citations, reference lists, and bibliographies.
← Back to Search

AHA/ACC Guidelines For Secondary Prevention For Patients With Coronary And Other Atherosclerotic Vascular Disease: 2006 Update: Endorsed By The National Heart, Lung, And Blood Institute.

S. Smith, J. Allen, S. Blair, R. Bonow, L. Brass, G. Fonarow, S. Grundy, L. Hiratzka, D. Jones, H. Krumholz, L. Mosca, R. Pasternak, T. Pearson, M. Pfeffer, K. Taubert
Published 2006 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Since the 2001 update of the American Heart Association (AHA)/American College of Cardiology (ACC) consensus statement on secondary prevention,1 important evidence from clinical trials has emerged that further supports and broadens the merits of aggressive risk-reduction therapies for patients with established coronary and other atherosclerotic vascular disease, including peripheral arterial disease, atherosclerotic aortic disease, and carotid artery disease. This growing body of evidence confirms that aggressive comprehensive risk factor management improves survival, reduces recurrent events and the need for interventional procedures, and improves quality of life for these patients. Compelling evidence from recent clinical trials and revised practice guidelines provided the impetus for this update of the 2001 recommendations with evidence-based results (Table 1⇓). Classification of Recommendations and Level of Evidence are expressed in ACC/AHA format, as detailed in Tables 2 and 3⇓. Recommendations made herein are based largely on major practice guidelines from the National Institutes of Health and ACC/AHA. In many cases, these practice guidelines were supplemented by research findings published after the publication of the primary reference(s). Thus, the development of the present statement involved a process of partial adaptation of other guideline statements and reports and supplemental literature searches.2–32 (For specific search criteria, see the Appendix.) The findings from additional lipid reduction trials33–37 involving more than 50 000 patients resulted in new optional therapeutic targets, which were outlined in the 2004 update of the National Heart, Lung, and Blood Institute’s Adult Treatment Panel (ATP) III report.6 These changes defined optional lower target cholesterol levels for very high-risk coronary heart disease (CHD) patients, especially those with acute coronary syndromes, and expanded indications for drug treatment. …
This paper references
Nutrition Committee. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease Erratum in: Circulation
Pm Kris-Etherton (2002)
American Heart Association Circulation
(2006)
10.1016/j.jacc.2005.12.001
ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention).
S. Smith (2006)
10.1056/NEJMOA042739
Angiotensin-converting-enzyme inhibition in stable coronary artery disease.
E. Braunwald (2004)
ACC / AHA / SCAI
SC Smith (2005)
10.1161/01.CIR.0000075572.40158.77
Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Ph
P. Thompson (2003)
10.1016/S0140-6736(03)14283-3
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial
J. McMurray (2003)
Angiotensin - convertingenzyme inhibition in stable coronary artery disease
E Braunwald (2005)
10.1161/CIRCULATIONAHA.105.170815
ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to update the 2001 Guidelines for Percutaneous Coronary Intervention
S. C. Smith (2006)
10.1161/01.CIR.0000145546.97738.1E
Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation.
S. Klein (2004)
10.1016/j.jacc.2004.08.002
ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery).
K. Eagle (2004)
10.1113/JPHYSIOL.2006.113472
Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement.
S. Grundy (2006)
10.1161/CIRCULATIONAHA.105.167586
ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult
S. Hunt (2005)
of Health
UK Departmen (2006)
Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease
JC LaRosa (2005)
AHA Scientific Statements Ⅲ coronary disease Ⅲ vascular diseases Ⅲ risk factors Ⅲ prevention 2372 Circulation May 16
Key (2006)
10.2337/DIACARE.29.02.06.DC05-1989
Standards of Medical Care in Diabetes: Response to Power
V. Fonseca (2006)
10.1161/01.ATV.0000089628.63625.D4
Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease.
P. Thompson (2003)
10.1161/01.CIR.0000114834.85476.81
Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women
L. Mosca (2004)
American Heart Association. Nutrition Committee. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease
PM Kris-Etherton (2002)
10.1161/01.CIR.0000109488.62415.01
Five-Year Follow-Up After Intracoronary Gamma Radiation Therapy for In-Stent Restenosis
R. Waksman (2004)
10.1001/JAMA.1995.03520290054029
Physical activity and public health. A recommendation from the Centers for Disease Control and Prevention and the American College of Sports Medicine.
R. Pate (1995)
10.1161/01.atv.0000133317.49796.0e
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.
S. Grundy (2004)
10.1001/JAMA.288.23.2998
Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).
C. Furberg (2002)
National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health
10.1161/01.ATV.0000121481.56512.C6
Summary of the American Heart Association’s Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women
L. Mosca (2004)
10.1161/HC3801.097475
AHA/ACC Scientific Statement: AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update: A statement for healthcare professionals from the American Heart Association and the American College of Cardiology.
S. Smith (2001)
10.1001/JAMA.294.19.2437
High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial.
T. Pedersen (2005)
American Heart Association. Nutrition Committee. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation
PM Kris-Etherton (2002)
American Stroke Association. Anticoagulants and antiplatelet agents in acute ischemic stroke: report of the Joint Stroke Guideline Development Committee of the
Bm Coull (2002)
10.1056/NEJMOA040583
Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
C. Cannon (2004)
10.1016/S0140-6736(03)12948-0
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial
P. Sever (2003)
10.1161/01.CIR.102.10.1193
ACC/AHA Guidelines for the Management of Patients With Unstable Angina and Non–ST-Segment Elevation Myocardial Infarction: Executive Summary and Recommendations
E. Braunwald (2000)
10.1001/JAMA.1995.03530070031016
Physical activity and public health.
P. T. Williams (1995)
10.1161/01.STR.0000028456.18614.93
Anticoagulants and antiplatelet agents in acute ischemic stroke: Report of the Joint Stroke Guideline Development Committee of the American Academy of Neurology and the American Stroke Association (a Division of the American Heart Association)
B. Coull (2002)
10.1037/e548512006-001
Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP).
C. Bridges (2001)
10.1016/S0140-6736(05)67394-1
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins
Cholesterol Treatment Trialists' Collaborators (2005)
10.1016/S0140-6736(02)09327-3
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial
A. Coats (2002)
10.1016/S1062-1458(02)00686-4
Improving quality of care for acute myocardial infarction: The Guidelines Applied in Practice (GAP) Initiative.
R. Mehta (2002)
10.1097/00019048-200106000-00021
Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).
S. Grundy (2001)
At Least Five a Week: Evidence on the Impact of Physical Activity and Its Relationship to Health: A Report From the Chief Medical Officer. London, England: Wellington House Available at: http://www
Uk Department (1995)
10.1016/J.JACC.2004.07.014
ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction
E. Antman (2004)
MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20536 high-risk individuals : a randomised placebo-controlled trial.
S. Feasson (2008)
update : a statement for healthcare professionals from the American Heart Association and the American College of Cardiology
L Mosca
Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
A V Chobanian
National High Blood Pressure Education Program.
C. Lenfant (1986)
10.1016/S0735-1097(02)02848-6
ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina).
R. Gibbons (2003)
10.1056/NEJMOA032292
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.
M. Pfeffer (2003)
Physical Activity and Health: A Report of the Surgeon General. Atlanta, Ga: US Department of Health and Human Services
Us Department (1996)
PROSPER study group. PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial
J Shepherd (2002)
10.1161/CIRCULATIONAHA.106.173220
ACC/AHA/SCAI Practice Guidelines, February 21, 2006
Lippincott Williams Wilkins (2006)
10.1016/J.ACCREVIEW.2004.10.005
Early Intensive vs a Delayed Conservative Simvastatin Strategy in Patients With Acute Coronary Syndromes
J. D. Lemos (2004)
Ann Thorac Surg
(2005)
AHA Scientific Statements Ⅲ coronary disease Ⅲ vascular diseases Ⅲ risk factors Ⅲ prevention
Key Words
At Least Five a Week: Evidence on the Impact of Physical Activity and Its Relationship to Health: A Report From the Chief Medical Officer
Uk Department (2004)
10.1016/J.ATHORACSUR.2005.01.008
The Society of Thoracic Surgeons practice guideline series: aspirin and other antiplatelet agents during operative coronary revascularization (executive summary).
V. Ferraris (2005)
10.1016/J.ACCREVIEW.2003.12.039
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both
M. Pfeffer (2004)
The Health Consequences of Smoking: A Report of the Surgeon General
Office on Smoking (2004)
10.1037/e565682010-001
Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults--The Evidence Report. National Institutes of Health.
Treatment of Obesity in Adults (1998)
10.2337/diacare.27.2007.s15
Standards of medical care in diabetes.
H. J. Morris (2005)
10.1016/s0735-1097(02)02336-7
ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients
E. Braunwald (2002)
Nutrition Committee. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease
(2002)
10.1001/JAMA.289.19.2560
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.
A. Chobanian (2003)
10.1016/S0140-6736(02)11600-X
Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial
J. Shepherd (2002)
10.1016/j.accreview.2004.04.078
Get with the guidelines for cardiovascular secondary prevention: pilot results.
K. LaBresh (2004)
of Health and Human Services
U. S. Departmen (2006)
WORDS: AHA Scientific Statements Ⅲ coronary disease Ⅲ vascular diseases Ⅲ risk factors Ⅲ prevention 2139
Physical activity and public health: a recommendation from the
Rr Pate (1995)
Diagnosis and management of the metabolic syndrome
S. M. Grundy (2005)
El tratamiento hipolipemiante intensivo frente al moderado con estatinas tras síndromes coronarios agudos
C. Cannon (2004)
10.1016/s1062-1458(02)00911-x
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary
S. Yusuf (2002)
10.1016/S0140-6736(06)68169-5
Efficacy and safety of cholesterol-lowering treatment
I. Abraha (2006)
10.1016/S0140-6736(05)67394-1
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.
C. Baigent (2005)
10.1001/JAMA.292.11.1307
Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial.
J. D. de Lemos (2004)
Nutrition Committee . Fish consumption , fish oil , omega - 3 fatty acids , and cardiovascular disease
PM Kris-Etherton (2004)
PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial
J Shepherd (2002)
ACC/AHA guideline for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction
E. Braunwald (2000)
10.1161/01.HYP.0000107251.49515.C2
Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.
A. Chobanian (2003)
10.1016/J.AHJ.2005.10.009
Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) Study.
I. Galin (2006)
At Least Five a Week: Evidence on the Impact of Physical Activity and Its Relationship to Health: A Report From the Chief Medical Officer
American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute
SM Grundy (2005)
Society of Thoracic Surgeons. The Society of Thoracic Surgeons practice guideline series: aspirin and other antiplatelet agents during operative coronary revascularization
V A Ferraris
10.1161/01.CIR.0000138790.14877.7D
ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery).
K. Eagle (2004)
10.1001/ARCHINTE.164.2.203
Get With the Guidelines for Cardiovascular Secondary Prevention
K. LaBresh (2004)
10.1161/01.STR.30.2.281
The american stroke association : A division of the american heart association
Fuster (1999)
10.1016/s0022-3182(97)70145-6
Physical Activity And Health: A Report Of The Surgeon General
A. F. Manley (2004)
10.1161/01.CIR.0000038493.65177.94
Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease.
P. Kris-Etherton (2003)
10.1016/J.ACCREVIEW.2003.10.014
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting enzyme inhibitors: the CHARM-alternative trial
C. Granger (2004)
10.1016/J.AHJ.2004.11.023
Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: The Vytorin Versus Atorvastatin (VYVA) Study
C. Ballantyne (2005)
10.1161/circ.110.14.e340
ACC/AHA 2004 Guideline Update for Coronary Artery Bypass Graft Surgery
Lippincott Williams Wilkins (2004)
10.1037/e548732006-001
Public health strategies for preventing and controlling overweight and obesity in school and worksite settings: a report on recommendations of the Task Force on Community Preventive Services.
D. Katz (2005)
10.1161/01.CIR.0000133317.49796.0E
Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
S. Grundy (2004)
ACC / AHA
KA Eagle (2004)
Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement Errata in: Circulation
Sm Grundy (2005)
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial Summary for patients in
(2002)
10.1016/j.jacc.2004.07.002
ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients wi
E. Antman (2004)
10.1016/S0735-1097(01)01682-5
AHA/ACC Guidelines for Preventing Heart Attack and Death in Patients With Atherosclerotic Cardiovascular Disease: 2001 update. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology.
S. Smith (2001)
10.1161/CIRCULATIONAHA.105.169404
Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement
S. Grundy (2005)
10.1016/j.jvs.2005.04.037
Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
J. Larosa (2005)
10.1093/AJCN/68.4.899
Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: executive summary. Expert Panel on the Identification, Evaluation, and Treatment of Overweight in Adults.
F. Pi-Sunyer (1998)



This paper is referenced by
10.1016/B978-1-4160-6231-8.10041-8
CHAPTER 41 – Diagnosis and Management of Coronary Artery Disease
W. Aronow (2010)
10.3810/pgm.2011.01.2247
Pharmacokinetics, Drug Metabolism, and Safety of Prasugrel and Clopidogrel
S. Achar (2011)
10.1186/1471-2458-14-1065
Men in Macau SAR have higher prevalence in metabolic syndrome and among related metabolic components: a cross-sectional Macau Health Survey
T. Sobko (2014)
10.1161/CIRCULATIONAHA.106.681148
Outcomes of Coronary Artery Bypass Grafting Versus Percutaneous Coronary Intervention With Drug-Eluting Stents for Patients With Multivessel Coronary Artery Disease
A. Javaid (2007)
10.1177/1358863X06076103
ACCF/SCAI/SVMB/SIR/ASITN 2007 Clinical Expert Consensus Document on Carotid Stenting
E. Bates (2007)
10.4065/82.5.543
Achieving low-density lipoprotein cholesterol goals in high-risk patients in managed care: comparison of rosuvastatin, atorvastatin, and simvastatin in the SOLAR trial.
W. Insull (2007)
10.1007/S11897-006-0017-7
Diabetes and heart failure in the post-myocardial infarction patient
J. Estep (2006)
10.1016/J.ATHORACSUR.2007.01.053
Quality measurement in adult cardiac surgery: part 1--Conceptual framework and measure selection.
D. Shahian (2007)
10.1016/J.DDMEC.2008.10.004
HDL – a difficult friend
A. Eckardstein (2008)
10.3810/pgm.2009.01.1952
Appropriate Secondary Prevention of Acute Atherothrombotic Events and Strategies to Improve Guideline Adherence
S. Rockson (2009)
10.3810/pgm.2009.01.1955
The Potential Role of Prasugrel in Secondary Prevention of Ischemic Events in Patients with Acute Coronary Syndromes
P. Toth (2009)
10.1161/STR.0b013e3181d2da7d
Translating Evidence Into Practice: A Decade of Efforts by the American Heart Association/American Stroke Association to Reduce Death and Disability Due to Stroke: A Presidential Advisory From the American Heart Association/American Stroke Association
L. Schwamm (2010)
10.1016/j.ypmed.2010.11.017
Physician support for a population-based pharmaceutical approach to cardiovascular prevention: not there yet.
Christina Huy (2011)
Alcohol consumption in relation to cardiovascular risk and mortality
Simona Costanzo (2012)
10.1185/030079907X182059
Efficacy and safety of ezetimibe co-administered with atorvastatin in untreated patients with primary hypercholesterolaemia and coronary heart disease
M. Blagden (2007)
10.1016/j.ijnurstu.2010.06.005
The effects of a tailored cardiac rehabilitation program on depressive symptoms in women: A randomized clinical trial.
T. Beckie (2011)
10.1016/j.athoracsur.2009.12.001
Effect of preoperative statin therapy on patients undergoing isolated and combined valvular heart surgery.
M. Borger (2010)
10.1016/j.jacl.2009.12.006
Another treatment gap: restarting secondary prevention medications: the Women's Health Initiative.
J. Robinson (2010)
10.1007/s11883-010-0150-3
What Combination Therapy with a Statin, If Any, Would You Recommend?
C. Dujovne (2011)
10.2215/CJN.11441111
Use of secondary prevention medications among adults with reduced kidney function.
T. Chang (2012)
10.1136/thx.2007.081893
Use of β blockers and the risk of death in hospitalised patients with acute exacerbations of COPD
M. Dransfield (2007)
10.1253/CIRCJ.CJ-10-0813
Efficacy of out-patient cardiac rehabilitation in low prognostic risk patients after acute myocardial infarction in primary intervention era.
Tsukasa Kamakura (2011)
10.1136/gut.2009.199695
Chronic gastrointestinal ischaemia: shifting paradigms
P. Mensink (2010)
10.1111/j.1751-7176.2008.00012.x
ASH Position Paper: Treatment of Hypertension in Patients With Diabetes—An Update
G. Bakris (2008)
10.1185/03007990903223895
Polyvascular atherosclerotic disease: recognizing the risks and managing the syndrome
S. Yakubov (2009)
10.3892/etm.2017.4903
Investigation of standardized administration of anti-platelet drugs and its effect on the prognosis of patients with coronary heart disease.
C. Ding (2017)
10.1161/CIRCULATIONAHA.109.869008
Efficacy and Safety of Varenicline for Smoking Cessation in Patients With Cardiovascular Disease: A Randomized Trial
N. Rigotti (2010)
10.1001/jama.2013.279206
Association between influenza vaccination and cardiovascular outcomes in high-risk patients: a meta-analysis.
J. Udell (2013)
10.1007/s11739-012-0791-z
Aspirin for the primary prevention of cardiovascular diseases
L. Tagliabue (2012)
10.2217/pgs.11.115
Integrative genomics strategies to elucidate the complexity of drug response.
A. Kasarskis (2011)
10.1111/j.1742-1241.2011.02753.x
Statins in non‐ischaemic cardiomyopathy: an update on our current clinical and pathophysiological understanding
N. Verma (2011)
10.1007/S12170-011-0191-3
Comprehensive Lipid Management in the Coronary Artery Disease Patient
N. Amin (2011)
See more
Semantic Scholar Logo Some data provided by SemanticScholar